×

Get the Free Prostate Cancer Patient Guide. Enter your email to get the pdf.

Please leave this field empty

Go here to learn more or to get a mailed copy.

10/06/2016

Progress Report: Atish Choudhury, MD, Ph.D

Investigator: Atish Choudhury, MD, PhD – Assistant Professor, Dana-Farber Cancer Institute Molecular Determinants of Hormone Refractory Prostate Cancer Metastatic prostate cancer initially responds to androgen deprivation therapy (ADT; blockade of male hormones such as testosterone) resulting in tumor regression and improved clinical performance. This is because prostate cancer cell growth. Read More

10/06/2016

Progress Report: Steve Y. Cho, MD

Investigator: Steve Y. Cho, MD – Assistant Professor, Johns Hopkins University Translation of [18F]DCFBC PET:A Novel Prostate Imaging Biomarker Positron Emission Tomography (PET) is a molecular imaging technique that can produce a 3-D image of human cancers. This system works by injecting a patient with a radionuclide tracer (a compound. Read More

10/06/2016

Progress Report: Tarek Bismar, MD

Investigator: Tarek Bismar, MD – Associate Professor, University of Calgary Combined role of TMPRSS2-ERG gene fusion and PTEN genomic deletions in prostate cancer progression The two most common genomic aberrations in prostate cancer are the ERG gene rearrangements and PTEN deletion. TMPRSS2-ERG represents the most common form of ERG rearrangements.. Read More

10/06/2016

Progress Report: Gerhardt Attard, MD, Ph.D

Investigator: Gerhardt Attard, MD, PhD – Assistant Professor, Institute for Cancer Research, Royal Marsden Hospital, London Predicting Resistance to Abiraterone: Molecular Analysis of CTCs First-line treatment for recurrent prostate cancer involves blockade of male hormone (testosterone; androgen) production in a process known as androgen deprivation therapy (ADT). Androgens are synthesized. Read More

10/06/2016

Progress Report: Mohamed Simon Arredouani, Ph.D

Investigator: Mohamed Simon Arredouani, PhD – Assistant Professor, Beth Israel Deaconess Medical Center Advances in Prostate Cancer Immunotherapy The immune system protects humans and other mammals from disease by recognizing foreign invaders such as bacteria and viruses. It is also thought that tumor cells express molecules foreign to the patient. Read More

10/06/2016

Progress Report: Andrew Armstrong, MD, MSc

Investigator: Andrew Armstrong, MD, MSc – Associate Professor, Duke University Linking Epithelial and Stemness Plasticity with Prostate Cancer Metastasis and the Lethal Phenotype The mechanism by which cancer cells spread from the primary tumor to distant sites in the body (the process of metastasis) is not fully understood. Scientists hypothesize. Read More

10/06/2016

Progress Report: John Ward, MD

Investigator: John Ward, MD– Assistant Professor, M.D. Anderson Cancer Center, University of Texas Noninvasive Radiofrequency Field for the Targeted Destruction of Prostate Cancer Using Directed Gold Nanoparticles—Activated Gold Particles Could Provide Novel Means of Destroying Tumors Dr. Ward is investigating a new way to kill prostate cancer cells by targeting. Read More

10/06/2016

Progress Report: Muneesh Tewari, MD, Ph.D

Investigator: Muneesh Tewari, MD, PhD–Assistant Member, Fred Hutchinson Cancer Research Center, University of Washington Exosomal RNAs as Serum Prostate Cancer Biomarkers—Personalized Treatment and Better Prognostic Indicators May Become Reality Through MicroRNA Tumor Profiling Dr. Tewari and colleagues have discovered that cancer cells shed tiny vesicles from their membrane, much like. Read More

10/06/2016

Progress Report: Pier Paolo Pandolfi, MD, Ph.D

Investigator: Pier Paolo Pandolfi, MD, PhD–George C. Reisman Professor of Medicine, Harvard Medical School, Director, Cancer Genetics Program, Associate Director, Cancer Center Beth Israel Deaconess Medical Center Pro-Senescence Therapy for Prostate Cancer The human body has a number of mechanisms in place to protect against cancer growth and survival. One. Read More

10/06/2016

Progress Report: David Nanus, MD

Investigator: David Nanus, MD–Professor of Medicine, Professor of Urology, Mark W. Pasmantier Professor of Hematology and Oncology in Medicine at Weill Cornell Medical College Circulating Tumor Cell Biomarker Discovery of Taxotere Response Docetaxel (Taxotere) chemotherapy is the standard first line treatment for patients with castrate resistant prostate cancer (CRPC). Data. Read More